Population pharmacokinetic modeling and optimal sampling strategy for bayesian estimation of amikacin exposure in critically Ill septic patients

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 749-756

  Delattre, Isabelle K ^a   Musuamba, Flora T ^a   Nyberg, Joakim ^b   Taccone, Fabio S ^c   Laterre, Pierre François ^d   Verbeeck, Roger K ^a   Jacobs, Frédérique ^c   Wallemacq, Pierre E ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UPPSALA UNIVERSITY   (Sweden)

^c ERASME HOSPITAL   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

amikacin; Bayesian estimation; optimal sampling strategy; population pharmacokinetics; severe sepsis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CATECHOLAMINE; CEFEPIME; CEFTAZIDIME; CREATININE; MEROPENEM; PIPERACILLIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; COMPARTMENT MODEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SAMPLING; SEPSIS; SEPTIC SHOCK; STATISTICAL PARAMETERS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CREATININE; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; SEPSIS; TISSUE DISTRIBUTION;

EID: 78650277930     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f675c2     Document Type: Article

References (43)

1. Begg EJ, Barclay ML. Aminoglycosides 50 years on. Br J Clin Pharmacol. 1995;39:597-603.
2. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev. 1994;13:207-234.
3. Zaske DE. Aminoglycosides. In: EVans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics, Inc; 1992:14.1-47.
4. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharma-cokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755-773.
5. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005; 44:1009-1034.
6. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:1135-1151.
7. Power BM, Forbes AM, Van Heerden PV, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34:25-56.
8. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30:2145-2156.
9. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet. 1988;14:347-373.
10. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16:327-330.
11. Lugo G, Castañeda-Hernández G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med. 1997;25:806-811.
12. Lugo-Goytia G, Castañeda-Hernández G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother. 2000;34:1389-1394.
13. Fernández de Gatta MM, Mendez ME, Romano S, et al. Pharmacokinetics of amikacin in intensive care unit patients. J Clin Pharm Ther. 1996;21: 417-421.
14. Romano S, Del Mar Fdez de Gatta M, Calvo V, et al. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Investig. 1998;15:435-444.
15. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21:172-173.
16. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001;40:803-814.
17. Böttger HC, Oellerich M, Sybrecht GW. Use of aminoglycosides in critically ill patients: individualization of dosage using Bayesian statistics and pharmacokinetic principles. Ther Drug Monit. 1988;10:280-286.
18. Lugo G, Castañeda-Hernández G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit. 1997;19: 271-276.
19. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-1256.
20. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754-1758.
21. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
22. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-710.
23. Jolley ME. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol. 1981;5: 236-240.
24. Abbott Laboratories Diagnostics Division. TDxFLx/TDx Assays Manual. 1990.
25. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241-257.
26. Jonsson EN, Karlsson MO. Xpose an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
27. Delattre IK, Musuamba FT, Verbeeck RK, et al. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem. 2010; 43:589-598.
28. Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010; 14:R53.
29. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007; 24:2187-2197.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
31. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000;11:A0828.
32. Holford NHG. The visual predictive check superiority to standard diagnostic (Rorschach) plots [Abstract]. Abstracts of the Annual Meeting of the Population Approach Group in Europe (PAGE). 2005;14:738.
33. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.
34. Foracchia M, Hooker A, Vicini P, et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed. 2004;74:29-46.
35. Nyberg J, Hennig S, Karlsson MO, et al. PopED 2 [Abstract]. Abstracts of the Annual Meeting of the Population Approach Group in Europe (PAGE). 2008;17:1432.
36. Merlé Y, Mentré F. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Biopharm. 1995;23:101-125.
37. Hennig S, Nyberg J, Fanta S, et al. Application of the optimal design approach to improve therapeutic drug monitoring for cyclosporine [Abstract]. Abstracts of the Annual Meeting of the Population Approach Group in Europe (PAGE). 2008;17:1436.
38. Pronzato L, Walter E. Robust experiment design via stochastic approximation. Math Biosci. 1985;75:103-120.
39. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
40. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
41. Tod M, Rocchisani JM. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Comput Methods Programs Biomed. 1996;50: 13-22.
42. Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinetic Pharmacodyn. 2005;32:441-457.
43. Merlé Y, Mentré F. Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring. J Pharmacokinet Biopharm. 1999;27:85-101.